| Drug Name: | Acetazolamide (59-66-5) |
|---|---|
| PubChem ID: | 1986 |
| SMILES: | CC(=O)NC1=NN=C(S1)S(=O)(=O)N |
| InchiKey: | BZKPWHYZMXOIDC-UHFFFAOYSA-N |
| Therapeutic Category: | Anticonvulsants, Carbonic Anhydrase Inhibitors, Central Nervous System Agents, Diuretics, Enzyme Inhibitors, Natriuretic Agents |
| Molecular Weight (dalton) | : | 222.251 |
| LogP | : | -0.8561 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 6 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 115.04 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Primidone (125-33-7) | Osteomalacia | Antagonistic | Acetazolamide-induced interference with primidone absorption Case reports and metabolic studies | |
| Acetylsalicylic acid (50-78-2) | Toxic Reaction | Antagonistic | Carbonic anhydrase inhibitors affect the plasma pH, so that more of the salicylate exists in the un-ionised form, which can enter the CNS and other tissues more easily, leading to salicylate toxicity | Toxicity of combined therapy with carbonic anhydrase inhibitors and aspirin |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Acidosis | Parathyroid hormone (Q03431) | Because parathyroid hormone@ 1@25-dihydroxyvitamin D and carbonic anhydrase are thought to be involved in bone buffering@the marked acidosis seen in haemodialysis patients treated with acetazolamide may be due to impaired parathyroid hormone-mediated bone buffering [ ADR Type 2 ] | Severe metabolic acidosis and disturbances of calcium metabolism induced by acetazolamide in patients on haemodialysis |
| Acidosis Impair Parathyroid Hormone-Mediated Bone Buffering | Carbonic anhydrase 12 precursor (O43570) | Because parathyroid hormone, 1,25-dihydroxyvitamin D and carbonic anhydrase are thought to be involved in bone buffering,the marked acidosis seen in haemodialysis patients treated with acetazolamide may be due to impaired parathyroid hormone-mediated bone buffering. [ ADR Type 2 ] | Severe metabolic acidosis and disturbances of calcium metabolism induced by acetazolamide in patients on haemodialysis |
| Increase In Blood Flow | Carbonic anhydrase 12 precursor (O43570) | The inhibition of carbonic anhydrase activity by acetazolamide (AZ), which decreases the rate of CO2 conversion to HCO3-, causes the retention of CO2 in tissues and organs, and thus increases BF in specific organs,which lead to acetazolamide-induced increase in blood flow to rabbit organs. [ ADR Type 1 ] | Acetazolamide-induced increase in blood flow to rabbit organs is confirmed using colored microspheres Heart Vessels |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category